<DOC>
	<DOCNO>NCT00019812</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody trastuzumab locate tumor cell deliver tumor-killing substance without harm normal cell . Drugs use chemotherapy use different way make tumor cell stop divide stop grow die . Combining monoclonal antibody therapy chemotherapy may kill tumor cell . PURPOSE : Phase II trial study effectiveness trastuzumab plus paclitaxel treating patient metastatic breast cancer overexpresses HER2 .</brief_summary>
	<brief_title>Monoclonal Antibody Plus Chemotherapy Treating Patients With Metastatic Breast Cancer That Overexpresses HER2</brief_title>
	<detailed_description>OBJECTIVES : - Determine pharmacokinetics pharmacodynamics trastuzumab ( Herceptin ) paclitaxel patient HER2-overexpressing metastatic breast cancer . - Provide access trastuzumab paclitaxel patient . OUTLINE : Patients receive trastuzumab ( Herceptin ) IV 30-90 minute paclitaxel IV 1 hour weekly . Patients receive trastuzumab alone course 1 combination paclitaxel subsequent course . Courses repeat every 4 week patient achieve sustain complete response 8 week disease progression occur . PROJECTED ACCRUAL : A total 55 patient accrue study within 2 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm metastatic breast cancer HER2 overexpression Radiographically physically measurable disease biopsied safely local anesthesia Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : 18 Sex : Male female Menopausal status : Not specify Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : Neutrophil count least 1,000/mm^3 Platelet count least 75,000/mm^3 Hepatic : Bilirubin great 3 time upper limit normal ( ULN ) AST ALT great 5 time ULN Renal : Not specify Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : No prior trastuzumab Chemotherapy : Not specify Endocrine therapy : At least 2 week since prior hormonal therapy No concurrent hormone receptor therapy ( e.g. , tamoxifen armidex ) Radiotherapy : Localized palliative external beam radiotherapy allow Surgery : Not specify Other : Concurrent bisphosphonates allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2003</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>male breast cancer</keyword>
</DOC>